Regenerative Medical Technology Group files draft information statement for SEC review
RMTG•Record-date capital structure and voting power
Record-date capital structure:
- 13,138,968 common shares outstanding
- 1,050,000 Series AA preferred
- 1 Series CC preferred
- 9,870 Series DD preferred
Series AA preferred carried 67% of total voting power as of Aug. 17, 2026; majority holders listed as Benito Novas and Dave Christensen.
Shareholders approve higher authorized share count
Regenerative Medical Technology Group’s shareholders authorized an increase in common shares authorized to 400 million from 100 million.
Board cites conversion headroom for securities and warrants
Board action dated Aug. 17, 2026 targeted headroom for conversions tied to outstanding convertible securities and warrants totaling about 184,156,824 shares.
